Patient and treatment characteristics (N = 512)
| Parameter . | N (%) . |
|---|---|
| Median age, years | 58 |
| Range | 20-90 |
| Female sex | 254 (49.6) |
| ECOG PS 0-1 | 509 (99.4) |
| Stage I disease | 410 (80.1) |
| Extranodal disease | 113 (22.1) |
| B symptoms | 3 (0.6) |
| Stage II disease | 102 (19.9) |
| Extranodal disease | 14 (2.7) |
| B symptoms | 2 (0.4) |
| Grade | |
| 1-2 | 460 (89.8) |
| 3A or 3 NOS | 52 (10.2) |
| Median RT dose, Gy | 30 |
| Range | 24-52 |
| 24-30 | 345 (67.4) |
| >30-36 | 140 (27.3) |
| >36 | 27 (5.3) |
| Median pretreatment size, cm | 2.8 |
| Range | 0.2-10 |
| Unknown | 45 (8.8) |
| Median follow-up, mo | 52.3 |
| Range | 3.2-174.6 |
| BCL2 expression | |
| Positive | 281 (54.9) |
| Negative | 133 (26.0) |
| Unknown | 98 (19.1) |
| Parameter . | N (%) . |
|---|---|
| Median age, years | 58 |
| Range | 20-90 |
| Female sex | 254 (49.6) |
| ECOG PS 0-1 | 509 (99.4) |
| Stage I disease | 410 (80.1) |
| Extranodal disease | 113 (22.1) |
| B symptoms | 3 (0.6) |
| Stage II disease | 102 (19.9) |
| Extranodal disease | 14 (2.7) |
| B symptoms | 2 (0.4) |
| Grade | |
| 1-2 | 460 (89.8) |
| 3A or 3 NOS | 52 (10.2) |
| Median RT dose, Gy | 30 |
| Range | 24-52 |
| 24-30 | 345 (67.4) |
| >30-36 | 140 (27.3) |
| >36 | 27 (5.3) |
| Median pretreatment size, cm | 2.8 |
| Range | 0.2-10 |
| Unknown | 45 (8.8) |
| Median follow-up, mo | 52.3 |
| Range | 3.2-174.6 |
| BCL2 expression | |
| Positive | 281 (54.9) |
| Negative | 133 (26.0) |
| Unknown | 98 (19.1) |
Continuous variables are shown with ranges, and categorical variables with percentages in parentheses.
ECOG PS, Eastern Cooperative Oncology Group performance score; NOS, not otherwise specified.